STAAR Surgical (NASDAQ:STAA) Announces Quarterly Earnings Results

STAAR Surgical (NASDAQ:STAA) released its earnings results on Wednesday. The medical instruments supplier reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of $0.05 by $0.06, FiscalAI reports. The company had revenue of $83.41 million during the quarter, compared to the consensus estimate of $78.73 million. STAAR Surgical had a return on equity of 9.05% and a net margin of 1.13%. STAAR Surgical’s quarterly revenue was down 11.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.08 earnings per share.

Here are the key takeaways from STAAR Surgical’s conference call:

• Third-quarter net sales were $83.4 million, down 12% year over year due to the prior-year China deferred-sales comparison; excluding that item, sales grew 21%. China sales rose 31% on the adjusted comparison, while distributor unit shipments in the market were up 12.4% through the first nine months.
• Growth was broad outside China: sales increased 13%, led by 14% growth in the Americas and 31% growth in EMEA. APAC excluding China grew 4%, though Japan and South Korea faced market and currency headwinds.
• Third-quarter gross margin was 70.9%, pressured by ERP-related production inefficiencies, freight, tariffs, and inventory provisions; management said unit costs will remain elevated through year-end. It expects margin to improve in the fourth quarter and further in 2027 as production and yields recover.
• STAAR ended the quarter with $206.4 million in cash and investments and no debt, and its board authorized a $50 million share repurchase program. Management said nine-month results included record revenue, net income, and free cash flow.
• The company expects to begin first-in-human enrollment for two Collamer-based presbyopia products in the coming months, subject to regulatory authorizations. The trials are an early step in management’s plan to broaden its product portfolio; no launch timing or trial details were provided.

STAAR Surgical Stock Performance

NASDAQ:STAA opened at $27.72 on Thursday. STAAR Surgical has a one year low of $15.59 and a one year high of $35.87. The business’s 50-day simple moving average is $22.57 and its 200 day simple moving average is $23.61. The stock has a market cap of $1.39 billion, a price-to-earnings ratio of 393.68 and a beta of 1.22.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on STAA shares. Veritas Investment Research set a $31.00 price target on shares of STAAR Surgical in a report on Tuesday, September 29th. Wedbush decreased their price objective on shares of STAAR Surgical from $40.00 to $37.00 and set an “outperform” rating on the stock in a report on Thursday, August 13th. Zacks Research upgraded shares of STAAR Surgical from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 19th. UBS Group set a $34.00 target price on shares of STAAR Surgical in a report on Thursday. Finally, Jefferies Financial Group reduced their price target on shares of STAAR Surgical from $28.00 to $23.00 and set a “buy” rating for the company in a research report on Tuesday, September 22nd. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, STAAR Surgical has an average rating of “Hold” and an average price target of $29.00.

STAAR Surgical announced that its Board of Directors has initiated a share buyback program on Thursday, September 24th that allows the company to buy back $50 million in shares. This buyback authorization allows the medical instruments supplier to reacquire up to 5.2% of its shares through open market purchases. Share buyback programs are generally a sign that the company’s management believes its shares are undervalued.

STAAR Surgical News Summary

Here are the key news stories impacting STAAR Surgical this week:

• Positive Sentiment: Third-quarter revenue of $83.4 million exceeded estimates of about $78.7 million. GAAP EPS was $0.11 versus the $0.05 consensus; adjusted EPS was reported at $0.34, above the $0.19 estimate. STAAR Surgical Reports Third Quarter 2026 Results
• Positive Sentiment: The company outlined a $50 million share repurchase and a product-development goal of launching products every 18 to 24 months, potentially supporting shareholder returns and longer-term growth. STAAR outlines repurchase and product-launch plans
• Negative Sentiment: Revenue was still down 11.9% from a year earlier, tempering the impact of the estimate beats and raising questions about the pace of recovery. STAAR Surgical Reports Third Quarter Financial Results

About STAAR Surgical

STAAR Surgical is a medical device company focused on ophthalmic surgery and vision correction. The company develops, manufactures and markets implantable lenses and related products designed to reduce or eliminate dependence on glasses or contact lenses.

Its principal product line is the EVO Visian Implantable Collamer Lens (ICL), a lens implanted inside the eye to correct myopia, with or without astigmatism. Unlike procedures that remove corneal tissue, ICL surgery preserves the eye’s natural lens and is designed to be removable.